When someone you love is facing cancer, hope becomes personal. You hope for an earlier answer, a clearer picture, another possibility.
Most of us respond in the human ways that matter. We listen. We show up. We wear a ribbon.
At Persistent, those hopes belong to our families and colleagues too, and they give our expertise a purpose. In Healthcare, trust is not optional, so our approach is the same across every solution: AI assists, experts decide. We build in human review, explainability and traceable sources, and we report outcomes as workflow and productivity gains rather than promises of clinical results. That discipline is part of the code too.
Here is how our AI solutions carry the hope the pink ribbon stands for.
Hope for earlier answers
Time matters in cancer care, and so does context. CanImageIN brings together patient information, AI-assisted radiology analysis and standardized reporting to support early cancer screening and assessment. By combining cancer-risk context with radiology image review, it helps clinicians see a more complete picture sooner.
Our client work shows what this can look like in practice. For LungLifeAI, which works on early-stage lung cancer detection, Persistent built an AI algorithm to support circulating tumor cell (CTC) image analysis. The reported results were nearly 70% less analysis time and 62% fewer falsely detected CTCs. These are workflow gains, and they free expert time for what matters most: careful review and sound judgment.
Hope also starts at the front door of care. For an oncology care provider, an AI clinical intake engine made intake 4× faster and cut time spent reviewing routine documentation by 80%. This can help patients reach expert oncology guidance with less delay.
Hope for greater clarity
Onco-pathology is at the heart of cancer diagnosis, and whole-slide images are vast and intricate. EmPATHy supports pathologists with AI-assisted imaging analysis. It finds regions of interest, flags cancer-related abnormalities, assists with tissue classification and helps prepare preliminary reports. The pathologist stays in control. The aim is not to replace pathology expertise but to focus it, so specialists can spend their attention where it matters.
Hope for new possibilities
Every new cancer therapy begins as a question. Answering it means connecting evidence spread across oncology publications, databases and proprietary research. Pi-OmniKG, our biomedical knowledge graph, connects public and proprietary oncology data. Oncology tumor boards can use it to review complex cases against connected evidence, with a clear rationale, as they work toward a treatment consensus.
Cancer researchers can use it to explore relationships and investigate scientific questions with cited insights. In one client engagement, specialized AI models working with Pi-OmniKG supported biomedical evidence synthesis and cut discovery and clinical decision analysis effort by up to 60%.
Sc(AI)Mitra supports biomedical teams across the cancer research cycle, from literature review and spotting knowledge gaps to forming hypotheses, planning experiments and drafting experimental protocols. Scientists get more room for discovery and spend less time on cumbersome manual work.
From there, the search for potential cancer medicines moves in silico, onto the computer. Pi-AFDD brings cancer target identification, protein structure prediction, virtual screening and molecular docking into one early-discovery workflow. Running on specialized infrastructure, it can predict challenging protein structures that compute limits had previously held back. GenMolVS goes a step further. It uses agentic AI to propose new cancer drug candidates, then screens and ranks them under scientific oversight.
Together, these capabilities open new possibilities in the search for cancer treatments. They help research teams explore more ideas faster, with evidence that can be traced and justified.
Hope for research to move forward
Promising cancer research must be validated through clinical trials, and their success depends on rigorous execution and regulatory compliance. (AI)InSiteturns clinical trial protocol requirements and historical evidence into clinical site rankings that explain their reasoning, helping sponsors find the right sites for each study. CRA Assist uses agentic AI to bring information from clinical trial systems together. It flags site risks and protocol deviations for human review, so monitoring teams know where to act first.
Protocol writing itself can speed up. For a cancer-focused pharma client, Persistent’s NOVA solution supported GenAI-powered protocol development. The work went from weeks to days, with a reported 60% cost savings.
Behind every trial and submission is a mountain of documentation and a regulatory landscape that keeps changing. DocIntel classifies, extracts and validates information through governed document workflows, and sends exceptions to people for review. Reg(AI)ntel monitors regulatory updates and maps their impact, helping teams stay compliant when requirements change.
Why we wear hope
It’s easy to think of AI as something abstract: models, pipelines, infrastructure. But the work on someone’s screen can matter to someone waiting for an answer. An onco-pathologist reviews slides with sharper focus.
A cancer scientist tests a new hypothesis this week instead of next quarter. A clinical trial team spots a cancer hospital’s onboarding challenge long before it becomes a delay. Each of these moments is a small step toward faster, clearer, more confident delivery of cancer care.
That connection is why we wear hope. And it’s exactly why we put AI to work.
Explore our solutions and client stories, and talk to us about the use case that matters most to your organization.
Hope. It’s in our code. #WearHope
Author’s Profile
Dr. Akash Saggam
Senior Engineering Lead – Domain
Dr. Santosh Dixit
Chief Domain Expert (Healthcare and LifeSciences), Innovation Labs






